_id
695fc263c2e91020a7bd45b1
Ticker
0OCQ.LSE
Name
Transgene SA
Exchange
LSE
Address
400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405
Country
UK
Sector
Industry
Currency
EUR
Website
https://www.transgene.fr
Description
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Last Close
0.946
Volume
2
Current Price
0.946
Change
0.008
Last Updated
2026-01-08T14:42:43.313Z
Ipo Date
-
Market Cap
58506624
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
96000
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
20993000
Operating Income
-21597000
Interest Expense
920000
Pretax Income
-23660000
Net Income
-19295000
Eps
-0.14560869274613564
Dividends Per Share
-
Shares Outstanding
62275900
Income Tax Expense
-4365000
EBITDA
-22040000
Operating Margin
-22496.875
Total Other Income Expense Net
-2063000
Cash
16771999
Short Term Investments
-
Receivables
1889000
Inventories
-
Total Current Assets
21712000
Property Plant Equipment
13853000
Total Assets
40987000
Payables
6665000
Short Term Debt
28809000
Long Term Debt
-
Total Liabilities
44591000
Equity
-3604000
Bs_currency_symbol
-
Depreciation
700000
Change In Working Capital
-1432000
Cash From Operations
-18185000
Capital Expenditures
279000
Cash From Investing
-593000
Cash From Financing
20283000
Net Change In Cash
101999
Cf_currency_symbol
-
PE
-
PB
-34.78274350110988
ROE
535.377358490566
ROA
-47.07590211530485
FCF
-18464000
Fcf Percent
-192.33333333333334
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
1
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
5
Net Net Investing Score
1
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
96000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
20993000
Quarters > 0 > income Statement > operating Income
-21597000
Quarters > 0 > income Statement > interest Expense
920000
Quarters > 0 > income Statement > pretax Income
-23660000
Quarters > 0 > income Statement > net Income
-19295000
Quarters > 0 > income Statement > eps
-0.14560869274613564
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
132512693
Quarters > 0 > income Statement > income Tax Expense
-4365000
Quarters > 0 > income Statement > EBITDA
-22040000
Quarters > 0 > income Statement > operating Margin
-22496.875
Quarters > 0 > income Statement > total Other Income Expense Net
-2063000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
16771999
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1889000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
21712000
Quarters > 0 > balance Sheet > property Plant Equipment
13853000
Quarters > 0 > balance Sheet > total Assets
40987000
Quarters > 0 > balance Sheet > payables
6665000
Quarters > 0 > balance Sheet > short Term Debt
28809000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
44591000
Quarters > 0 > balance Sheet > equity
-3604000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-19295000
Quarters > 0 > cash Flow > depreciation
700000
Quarters > 0 > cash Flow > change In Working Capital
-1432000
Quarters > 0 > cash Flow > cash From Operations
-18185000
Quarters > 0 > cash Flow > capital Expenditures
279000
Quarters > 0 > cash Flow > cash From Investing
-593000
Quarters > 0 > cash Flow > cash From Financing
20283000
Quarters > 0 > cash Flow > net Change In Cash
101999
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.14560869274613564
Quarters > 0 > ratios > PB
-34.78274350110988
Quarters > 0 > ratios > ROE
535.377358490566
Quarters > 0 > ratios > ROA
-47.07590211530485
Quarters > 0 > ratios > FCF
-18464000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-192.33333333333334
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
2996000
Quarters > 1 > income Statement > cost Of Revenue
18855000
Quarters > 1 > income Statement > gross Profit
-15859000
Quarters > 1 > income Statement > operating Expenses
31536000
Quarters > 1 > income Statement > operating Income
-15829000
Quarters > 1 > income Statement > interest Expense
1139000
Quarters > 1 > income Statement > pretax Income
-20325000
Quarters > 1 > income Statement > net Income
-17486000
Quarters > 1 > income Statement > eps
-0.13253569271626173
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
131934271
Quarters > 1 > income Statement > income Tax Expense
-2839000
Quarters > 1 > income Statement > EBITDA
-18441000
Quarters > 1 > income Statement > operating Margin
-528.3377837116154
Quarters > 1 > income Statement > total Other Income Expense Net
-4496000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
16670000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
1186000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
20668000
Quarters > 1 > balance Sheet > property Plant Equipment
14293000
Quarters > 1 > balance Sheet > total Assets
42174000
Quarters > 1 > balance Sheet > payables
9500000
Quarters > 1 > balance Sheet > short Term Debt
181000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
26970000
Quarters > 1 > balance Sheet > equity
15204000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-17486000
Quarters > 1 > cash Flow > depreciation
745000
Quarters > 1 > cash Flow > change In Working Capital
13618000
Quarters > 1 > cash Flow > cash From Operations
-5708000
Quarters > 1 > cash Flow > capital Expenditures
1062000
Quarters > 1 > cash Flow > cash From Investing
-1760000
Quarters > 1 > cash Flow > cash From Financing
8419000
Quarters > 1 > cash Flow > net Change In Cash
1350000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.13253569271626173
Quarters > 1 > ratios > PB
8.209012126151013
Quarters > 1 > ratios > ROE
-115.00920810313076
Quarters > 1 > ratios > ROA
-41.46156399677526
Quarters > 1 > ratios > FCF
-6770000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-2.2596795727636847
Quarters > 1 > health Score
17
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
23000
Quarters > 2 > income Statement > cost Of Revenue
12089000
Quarters > 2 > income Statement > gross Profit
-12066000
Quarters > 2 > income Statement > operating Expenses
4429000
Quarters > 2 > income Statement > operating Income
-19829000
Quarters > 2 > income Statement > interest Expense
542000
Quarters > 2 > income Statement > pretax Income
-19692000
Quarters > 2 > income Statement > net Income
-16485000
Quarters > 2 > income Statement > eps
-0.1632877493566626
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
100956747
Quarters > 2 > income Statement > income Tax Expense
-3207000
Quarters > 2 > income Statement > EBITDA
-18542000
Quarters > 2 > income Statement > operating Margin
-86213.04347826088
Quarters > 2 > income Statement > total Other Income Expense Net
137000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
15320000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
2063000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
19121000
Quarters > 2 > balance Sheet > property Plant Equipment
14124000
Quarters > 2 > balance Sheet > total Assets
50752000
Quarters > 2 > balance Sheet > payables
7310000
Quarters > 2 > balance Sheet > short Term Debt
180000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
51368000
Quarters > 2 > balance Sheet > equity
-616000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-16485000
Quarters > 2 > cash Flow > depreciation
608000
Quarters > 2 > cash Flow > change In Working Capital
-2865000
Quarters > 2 > cash Flow > cash From Operations
-18133000
Quarters > 2 > cash Flow > capital Expenditures
2004000
Quarters > 2 > cash Flow > cash From Investing
-1446000
Quarters > 2 > cash Flow > cash From Financing
18833000
Quarters > 2 > cash Flow > net Change In Cash
-346000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.1632877493566626
Quarters > 2 > ratios > PB
-155.04071860714285
Quarters > 2 > ratios > ROE
2676.1363636363635
Quarters > 2 > ratios > ROA
-32.48147856242119
Quarters > 2 > ratios > FCF
-20137000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-875.5217391304348
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
3137000
Quarters > 3 > income Statement > cost Of Revenue
14019000
Quarters > 3 > income Statement > gross Profit
-10882000
Quarters > 3 > income Statement > operating Expenses
3832000
Quarters > 3 > income Statement > operating Income
-14714000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-6426000
Quarters > 3 > income Statement > net Income
-6426000
Quarters > 3 > income Statement > eps
-0.0633832824373269
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
101383200
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-13464000
Quarters > 3 > income Statement > operating Margin
-469.0468600573797
Quarters > 3 > income Statement > total Other Income Expense Net
8288000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
15666000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
17984000
Quarters > 3 > balance Sheet > property Plant Equipment
12314000
Quarters > 3 > balance Sheet > total Assets
45217000
Quarters > 3 > balance Sheet > payables
4545000
Quarters > 3 > balance Sheet > short Term Debt
1240000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
26517000
Quarters > 3 > balance Sheet > equity
15612000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-6426000
Quarters > 3 > cash Flow > depreciation
772000
Quarters > 3 > cash Flow > change In Working Capital
-916000
Quarters > 3 > cash Flow > cash From Operations
-17010000
Quarters > 3 > cash Flow > capital Expenditures
1265000
Quarters > 3 > cash Flow > cash From Investing
16672998
Quarters > 3 > cash Flow > cash From Financing
12283000
Quarters > 3 > cash Flow > net Change In Cash
11946000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.0633832824373269
Quarters > 3 > ratios > PB
6.143255649500385
Quarters > 3 > ratios > ROE
-41.16064565718678
Quarters > 3 > ratios > ROA
-14.211469137713692
Quarters > 3 > ratios > FCF
-18275000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-5.82562958240357
Quarters > 3 > health Score
16
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
6353000
Annuals > 0 > income Statement > cost Of Revenue
34278000
Annuals > 0 > income Statement > gross Profit
-27925000
Annuals > 0 > income Statement > operating Expenses
7733000
Annuals > 0 > income Statement > operating Income
-35658000
Annuals > 0 > income Statement > interest Expense
1681000
Annuals > 0 > income Statement > pretax Income
-40017000
Annuals > 0 > income Statement > net Income
-33971000
Annuals > 0 > income Statement > eps
-0.29117926789212645
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
116666960
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-26651800
Annuals > 0 > income Statement > operating Margin
-561.2781363135526
Annuals > 0 > income Statement > total Other Income Expense Net
1687000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
16670000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
1186000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
20668000
Annuals > 0 > balance Sheet > property Plant Equipment
14293000
Annuals > 0 > balance Sheet > total Assets
42174000
Annuals > 0 > balance Sheet > payables
9500000
Annuals > 0 > balance Sheet > short Term Debt
181000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
26970000
Annuals > 0 > balance Sheet > equity
15204000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-33971000
Annuals > 0 > cash Flow > depreciation
1281000
Annuals > 0 > cash Flow > change In Working Capital
10753000
Annuals > 0 > cash Flow > cash From Operations
-23548000
Annuals > 0 > cash Flow > capital Expenditures
3066000
Annuals > 0 > cash Flow > cash From Investing
-3206000
Annuals > 0 > cash Flow > cash From Financing
26959000
Annuals > 0 > cash Flow > net Change In Cash
1004000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-0.29117926789212645
Annuals > 0 > ratios > PB
7.25907288608261
Annuals > 0 > ratios > ROE
-223.43462246777165
Annuals > 0 > ratios > ROA
-80.54962773272632
Annuals > 0 > ratios > FCF
-26614000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-4.1892019518337795
Annuals > 0 > health Score
16
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
7900000
Annuals > 1 > income Statement > cost Of Revenue
29588000
Annuals > 1 > income Statement > gross Profit
-21688000
Annuals > 1 > income Statement > operating Expenses
8359000
Annuals > 1 > income Statement > operating Income
-30047000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-22328000
Annuals > 1 > income Statement > net Income
-22328000
Annuals > 1 > income Statement > eps
-0.2219706903450514
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
100589857
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-28440000
Annuals > 1 > income Statement > operating Margin
-380.34177215189874
Annuals > 1 > income Statement > total Other Income Expense Net
7719000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
15666000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
907000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
17984000
Annuals > 1 > balance Sheet > property Plant Equipment
12314000
Annuals > 1 > balance Sheet > total Assets
45217000
Annuals > 1 > balance Sheet > payables
4545000
Annuals > 1 > balance Sheet > short Term Debt
1332000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
29605000
Annuals > 1 > balance Sheet > equity
15612000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-22328000
Annuals > 1 > cash Flow > depreciation
1586000
Annuals > 1 > cash Flow > change In Working Capital
-7065000
Annuals > 1 > cash Flow > cash From Operations
-34671000
Annuals > 1 > cash Flow > capital Expenditures
2667000
Annuals > 1 > cash Flow > cash From Investing
34572000
Annuals > 1 > cash Flow > cash From Financing
11369000
Annuals > 1 > cash Flow > net Change In Cash
11263000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.2219706903450514
Annuals > 1 > ratios > PB
6.095183494875736
Annuals > 1 > ratios > ROE
-143.01819113502435
Annuals > 1 > ratios > ROA
-49.37965809319504
Annuals > 1 > ratios > FCF
-37338000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-4.72632911392405
Annuals > 1 > health Score
17
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
3126000
Annuals > 2 > income Statement > cost Of Revenue
32168000
Annuals > 2 > income Statement > gross Profit
-29042000
Annuals > 2 > income Statement > operating Expenses
33253000
Annuals > 2 > income Statement > operating Income
-29904000
Annuals > 2 > income Statement > interest Expense
804000
Annuals > 2 > income Statement > pretax Income
-32804000
Annuals > 2 > income Statement > net Income
-32810000
Annuals > 2 > income Statement > eps
-0.32974224829340043
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
99501960
Annuals > 2 > income Statement > income Tax Expense
6000
Annuals > 2 > income Statement > EBITDA
-30327000
Annuals > 2 > income Statement > operating Margin
-956.6218809980807
Annuals > 2 > income Statement > total Other Income Expense Net
-2900000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
4403000
Annuals > 2 > balance Sheet > short Term Investments
22423000
Annuals > 2 > balance Sheet > receivables
2935000
Annuals > 2 > balance Sheet > inventories
15976000
Annuals > 2 > balance Sheet > total Current Assets
46506000
Annuals > 2 > balance Sheet > property Plant Equipment
11177000
Annuals > 2 > balance Sheet > total Assets
66436000
Annuals > 2 > balance Sheet > payables
6965000
Annuals > 2 > balance Sheet > short Term Debt
1192000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
28595000
Annuals > 2 > balance Sheet > equity
37841000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-32804000
Annuals > 2 > cash Flow > depreciation
1686000
Annuals > 2 > cash Flow > change In Working Capital
5090000
Annuals > 2 > cash Flow > cash From Operations
-20303000
Annuals > 2 > cash Flow > capital Expenditures
1535000
Annuals > 2 > cash Flow > cash From Investing
20272000
Annuals > 2 > cash Flow > cash From Financing
-1477000
Annuals > 2 > cash Flow > net Change In Cash
-1508000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.32974224829340043
Annuals > 2 > ratios > PB
2.4874832631272956
Annuals > 2 > ratios > ROE
-86.70489680505273
Annuals > 2 > ratios > ROA
-49.38587512794268
Annuals > 2 > ratios > FCF
-21838000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-6.985924504158669
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
9993000
Annuals > 3 > income Statement > cost Of Revenue
32883000
Annuals > 3 > income Statement > gross Profit
-22890000
Annuals > 3 > income Statement > operating Expenses
33739000
Annuals > 3 > income Statement > operating Income
-23525000
Annuals > 3 > income Statement > interest Expense
464000
Annuals > 3 > income Statement > pretax Income
-19536000
Annuals > 3 > income Statement > net Income
-20004000
Annuals > 3 > income Statement > eps
-0.21955480138439817
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
91111649
Annuals > 3 > income Statement > income Tax Expense
468000
Annuals > 3 > income Statement > EBITDA
-23550000
Annuals > 3 > income Statement > operating Margin
-235.41479035324727
Annuals > 3 > income Statement > total Other Income Expense Net
4159000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
5911000
Annuals > 3 > balance Sheet > short Term Investments
43658000
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
62245000
Annuals > 3 > balance Sheet > property Plant Equipment
11295000
Annuals > 3 > balance Sheet > total Assets
101838000
Annuals > 3 > balance Sheet > payables
7692000
Annuals > 3 > balance Sheet > short Term Debt
1395000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
34629000
Annuals > 3 > balance Sheet > equity
67209000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-19536000
Annuals > 3 > cash Flow > depreciation
2521000
Annuals > 3 > cash Flow > change In Working Capital
-12798000
Annuals > 3 > cash Flow > cash From Operations
-31943000
Annuals > 3 > cash Flow > capital Expenditures
686000
Annuals > 3 > cash Flow > cash From Investing
16793000
Annuals > 3 > cash Flow > cash From Financing
15772000
Annuals > 3 > cash Flow > net Change In Cash
634000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.21955480138439817
Annuals > 3 > ratios > PB
1.2824416365962892
Annuals > 3 > ratios > ROE
-29.76387091014596
Annuals > 3 > ratios > ROA
-19.642962351970777
Annuals > 3 > ratios > FCF
-32629000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-3.2651856299409587
Annuals > 3 > health Score
31
Valuation > metrics > PE
-0.14560869274613564
Valuation > metrics > PB
-34.78274350110988
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
535.377358490566
Profitability > metrics > ROA
-88.86790714812085
Profitability > metrics > Net Margin
-200.98958333333334
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-23.475
Risk > final Score
-64
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.6120538986299825
Liquidity > metrics > Quick Ratio
0.6120538986299825
Liquidity > final Score
41
Liquidity > verdict
Weak
Prev Valuations > 0
20
Prev Valuations > 1
50
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
40
Prev Profitabilities > 2
0
Prev Risks > 0
-26
Prev Risks > 1
-116
Prev Risks > 2
22
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:14:18.856Z
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Transgene SA
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.